Sep 102012

We’re not clairvoyant, but we’re also not surprised that life science ATM financing slowed in the second quarter. There was a tremendous increase in all forms of follow-on offerings, including ATMs, in the first quarter of 2012, that went hand-in-hand with the stock market’s overall strong performance.

A summer slowdown doesn’t predict a trend to us: despite the decrease in capital raised, life science ATM sign-ups hit a quarterly record, and 50 life sciences companies now have ATMs available to raise capital when needed.

The growth trend is still in place, and some first-hand conversations we’ve had at recent life sciences events have us convinced that these firms are starting to recognize the benefits that ATMs bring to their financial toolkits.

Sep 062012
Michael Higgins, Managing Director, Brinson Patrick
Michael Higgins
Vernon Bernardino, Brinson Patrick
Vernon Bernardino

At the beginning of the year, Brinson Patrick quietly launched an equity research department to better serve its life sciences clients. They knew us, trusted us, and knew we knew their business inside and out, and adding the department made sense as an additional service to our DOCS® ATM financing vehicle.

It began as a team of one, with Michael Higgins, former managing director and senior specialty pharmaceuticals analyst with Rodman & Renshaw, LLC. Now it’s a powerhouse team of two, with the addition of senior analyst Vernon Bernardino, an 11-year veteran of biotech and pharmaceutical financial coverage.

We welcome Vernon, and look forward to leveraging our increased expertise to help clients develop successful financing strategies.

Aug 222012

Sickle Cell Conference We’re happy to announce that we’re attending, presenting and co-sponsoring the first annual Sickle Cell Disease Therapeutics Conference the third week of September, Wednesday 9/19.  This is a forum to discuss the latest advancements and future trends for treating patients with sickle cell disease. Brinson Patrick Managing Director and life sciences analyst Michael Higgins will be co-presenting The Patient Experience Q&A with sickle cell disease patient Andre Louissaint.  Learn more here, and see you there.

Jul 192012

Strategic CFOs in the life sciences industry are increasingly employing ATMs because they enable companies to better control the financing process and the relatively low cost compared to more traditional follow-on financing vehicles.

Med City: Common Misunderstandings of an Emerging Financing Vehicle: At-the-Market Offerings

Apr 242012

 U.S. companies raised approximately $8 billion through ATMs in 2011, compared to $8.3 billion in 2010. The equity capital raised was through the activity of 209 ATM offerings of common stock across 20 industries, compared to the activity of 187 ATM offerings in 2010. $1.6 Billion Raised in fourth quarter last year.

Brinson Patrick Reports $8 Billion Raised by U.S. Companies Through At-The-Market (ATM) Offerings in 2011

Mar 222012

Today we are announcing the initiation of research coverage of Akorn, Inc.(NASDAQ: AKRX), a company that develops, manufactures and markets multisource and branded pharmaceuticals. The report, issued by our analyst Michael Higgins, is the first one of the firm’s new equity research department, which was established in January.

Brinson Patrick Securities Initiates Research Coverage of Akorn, Inc.